Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 13/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 7/20 | 0.35 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.34 |
| ▸ | NNMT | P40261 | 5/20 | 0.33 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.32 |
| ▸ | ADK | P55263 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25047420 | 0.89 | PRMT5 (0.34) | PRMT5WDR77METTL3NNMTDOT1L | |
| SCHEMBL29743109 | 0.89 | PRMT5 (0.34) | PRMT5WDR77METTL3NNMTDOT1L | |
| SCHEMBL23120330 | 0.87 | PRMT5 (0.32) | PRMT5WDR77METTL3NNMT | |
| SCHEMBL9287692 | 0.81 | ADK (0.46) | PRMT5WDR77METTL3ADK | |
| SCHEMBL30941131 | 0.81 | NNMT (0.39) | PRMT5WDR77NNMT | |
| SCHEMBL23776516 | 0.81 | NNMT (0.39) | PRMT5WDR77NNMT | |
| SCHEMBL29743106 | 0.79 | PRMT5 (0.31) | PRMT5WDR77 | |
| SCHEMBL23121274 | 0.79 | PRMT5 (0.46) | PRMT5WDR77METTL3 | |
| SCHEMBL23120208 | 0.79 | PRMT5 (0.37) | PRMT5WDR77METTL3 | |
| SCHEMBL20049564 | 0.77 | PDPK1 (0.34) | PRMT5WDR77METTL3NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220184195-A1 | INHIBITION OF HISTONE METHYL TRANSFERASES TO TREAT CANCER | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2022-06-16 | — | — | US | disclosed |
| WO-2021053158-A1 | NOVEL HISTONE METHYLTRANSFERASE INHIBITORS | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184195-A1 | INHIBITION OF HISTONE METHYL TRANSFERASES TO TREAT CANCER | KMT2A, KMT5A, DOT1L | PRMT5 84/4885WDR77 111/4885METTL3 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.